发布求助
文献互助 智能选刊 最新文献

Immuno-oncology technology最新文献

筛选
英文 中文
45P Prospective immunophenotyping to predict clinical outcomes in small cell lung cancer 前瞻性免疫表型预测小细胞肺癌的临床预后
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101128
S. Shi , M. Blasi , F. Bozorgmehr , R. Shah , A. Kühn , F. Eichhorn , M. Schneider , M. Allgäuer , D. Kazdal , A. Stenzinger , M. Thomas , P. Christopoulos
{"title":"45P Prospective immunophenotyping to predict clinical outcomes in small cell lung cancer","authors":"S. Shi , M. Blasi , F. Bozorgmehr , R. Shah , A. Kühn , F. Eichhorn , M. Schneider , M. Allgäuer , D. Kazdal , A. Stenzinger , M. Thomas , P. Christopoulos","doi":"10.1016/j.iotech.2025.101128","DOIUrl":"10.1016/j.iotech.2025.101128","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101128"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
100P ARI-HER2: Preclinical basis for a first-in-human CAR-T Trial in HER2+ breast cancer (BS) 100P ARI-HER2: HER2阳性乳腺癌首次人体CAR-T试验的临床前基础
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101185
L. Angelats , A. Rodriguez Garcia , T. Lobo-Jarne , V. Albarrán-Fernández , S. Colell , M. Giménez-Alejandre , G. Colell , C. Barcelo , M. Hernandez , P. Galván , E. Sanfeliu Torres , A. Martínez-Romero , F. Brasó-Maristany , A. Prat , S. Guedan
{"title":"100P ARI-HER2: Preclinical basis for a first-in-human CAR-T Trial in HER2+ breast cancer (BS)","authors":"L. Angelats , A. Rodriguez Garcia , T. Lobo-Jarne , V. Albarrán-Fernández , S. Colell , M. Giménez-Alejandre , G. Colell , C. Barcelo , M. Hernandez , P. Galván , E. Sanfeliu Torres , A. Martínez-Romero , F. Brasó-Maristany , A. Prat , S. Guedan","doi":"10.1016/j.iotech.2025.101185","DOIUrl":"10.1016/j.iotech.2025.101185","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101185"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
43P Biomarker-driven response to PD-1 + LAG-3 blockade in advanced melanoma 43P生物标志物驱动的PD-1 + LAG-3阻断在晚期黑色素瘤中的反应
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101126
H.T. Hashim
{"title":"43P Biomarker-driven response to PD-1 + LAG-3 blockade in advanced melanoma","authors":"H.T. Hashim","doi":"10.1016/j.iotech.2025.101126","DOIUrl":"10.1016/j.iotech.2025.101126","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101126"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
78P Dynamic immune modulation by dendritic cell vaccination and IFN-α in advanced melanoma: Final insights from the ABSIDE phase II trial 通过树突状细胞疫苗和IFN-α在晚期黑色素瘤中的动态免疫调节：ABSIDE II期试验的最终见解
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101163
J. Bulgarelli
{"title":"78P Dynamic immune modulation by dendritic cell vaccination and IFN-α in advanced melanoma: Final insights from the ABSIDE phase II trial","authors":"J. Bulgarelli","doi":"10.1016/j.iotech.2025.101163","DOIUrl":"10.1016/j.iotech.2025.101163","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101163"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
30P Targeted transcriptomic analysis of inflammation related genes in long-term survivors and early progressors in patients with advanced NSCLC receiving PD-(L)1 therapy 在接受PD-(L)1治疗的晚期NSCLC患者中，长期存活者和早期进展者炎症相关基因的靶向转录组学分析
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101113
M. García Pardo de Santayana , T. Caniego-Casas , M.E. Olmedo Garcia , A. Santón , J. Chamorro-Perez , Y. Lage , A. Gomez Rueda , E.M. Cristobal , A. Benito Berlinches , S. Aso , N.I. Torres , J. Palacios Calvo , P. Garrido Lopez
{"title":"30P Targeted transcriptomic analysis of inflammation related genes in long-term survivors and early progressors in patients with advanced NSCLC receiving PD-(L)1 therapy","authors":"M. García Pardo de Santayana , T. Caniego-Casas , M.E. Olmedo Garcia , A. Santón , J. Chamorro-Perez , Y. Lage , A. Gomez Rueda , E.M. Cristobal , A. Benito Berlinches , S. Aso , N.I. Torres , J. Palacios Calvo , P. Garrido Lopez","doi":"10.1016/j.iotech.2025.101113","DOIUrl":"10.1016/j.iotech.2025.101113","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101113"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
22P 4-1BB expression in tumor-infiltrating T cells predicts immune checkpoint inhibitor benefit through tertiary lymphoid structure: Mediated immune priming in advanced non-small cell lung cancer 22p4 - 1bb在肿瘤浸润性T细胞中的表达通过三级淋巴结构：介导的免疫启动在晚期非小细胞肺癌中预测免疫检查点抑制剂的益处
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101105
F. Peyraud , J-P. Guégan , B. Besse , S. Cousin , M. Cabart , F. Chomy , C. Rey , O. Lara , O. Odin , I. Nafia , L. Vanhersecke , F. Barlesi , A. Bessede , A. Italiano
{"title":"22P 4-1BB expression in tumor-infiltrating T cells predicts immune checkpoint inhibitor benefit through tertiary lymphoid structure: Mediated immune priming in advanced non-small cell lung cancer","authors":"F. Peyraud , J-P. Guégan , B. Besse , S. Cousin , M. Cabart , F. Chomy , C. Rey , O. Lara , O. Odin , I. Nafia , L. Vanhersecke , F. Barlesi , A. Bessede , A. Italiano","doi":"10.1016/j.iotech.2025.101105","DOIUrl":"10.1016/j.iotech.2025.101105","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101105"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
34P Serum levels of matrix proteins and cysteine-rich angiogenic inducer 61 in breast cancer 34P基质蛋白及富半胱氨酸血管生成诱导剂61在乳腺癌中的血清水平
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101117
L. Karimova , I. Shahverdiyeva , G. Azizova
{"title":"34P Serum levels of matrix proteins and cysteine-rich angiogenic inducer 61 in breast cancer","authors":"L. Karimova , I. Shahverdiyeva , G. Azizova","doi":"10.1016/j.iotech.2025.101117","DOIUrl":"10.1016/j.iotech.2025.101117","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101117"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145837264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
117eP In vitro assessment of an EphA2-targeting CAR-T cell therapy for NSCLC 靶向epha2的CAR-T细胞治疗非小细胞肺癌的体外评估
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101202
R.S. Tan , N. Sereesongsaeng , R. D'Souza , A. Furness , T. Rabbitts , A. Klampatsa
{"title":"117eP In vitro assessment of an EphA2-targeting CAR-T cell therapy for NSCLC","authors":"R.S. Tan , N. Sereesongsaeng , R. D'Souza , A. Furness , T. Rabbitts , A. Klampatsa","doi":"10.1016/j.iotech.2025.101202","DOIUrl":"10.1016/j.iotech.2025.101202","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101202"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
19P Automated quantification of tumor-infiltrating lymphocytes by machine learning reveals prognostic and immunogenomic features in lung cancer 通过机器学习自动定量肿瘤浸润淋巴细胞揭示肺癌的预后和免疫基因组特征
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101103
A. Li, F. Li
{"title":"19P Automated quantification of tumor-infiltrating lymphocytes by machine learning reveals prognostic and immunogenomic features in lung cancer","authors":"A. Li, F. Li","doi":"10.1016/j.iotech.2025.101103","DOIUrl":"10.1016/j.iotech.2025.101103","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101103"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab ipilimumab和nivolumab联合进行分离肝灌注的转移性葡萄膜黑色素瘤患者的纵向ctDNA监测
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-10-26 DOI: 10.1016/j.iotech.2025.101079
M. Kadefors , A. Nelson , E. Blomberg , A. Ståhlberg , L. Ny , R. Olofsson Bagge
{"title":"Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab","authors":"M. Kadefors ,&nbsp;A. Nelson ,&nbsp;E. Blomberg ,&nbsp;A. Ståhlberg ,&nbsp;L. Ny ,&nbsp;R. Olofsson Bagge","doi":"10.1016/j.iotech.2025.101079","DOIUrl":"10.1016/j.iotech.2025.101079","url":null,"abstract":"<div><h3>Background</h3><div>Uveal melanoma (UM) is a rare cancer, which often metastasizes to the liver, leading to a poor prognosis. In the randomized SCANDIUM II trial, patients with metastatic UM received a one-time treatment with isolated hepatic perfusion using high-dose melphalan in combination with systemic immune checkpoint inhibition with ipilimumab (3 mg/kg) and nivolumab (1 mg/kg). In this study, we assessed circulating tumor DNA (ctDNA) in prospectively collected blood samples from all patients in the SCANDIUM II trial to detect residual disease and recurrence as a strategy to evaluate treatment efficacy and predict prognosis.</div></div><div><h3>Patients and methods</h3><div>We analyzed ctDNA in 128 plasma samples from 18 patients using digital PCR (Oncobit™ PM) targeting GNA11 Q209L (<em>n</em> = 9), GNAQ Q209P (<em>n</em> = 5), or GNAQ Q209L (<em>n</em> = 4).</div></div><div><h3>Results</h3><div>At baseline, ctDNA was detectable in 9 of 17 (53%) patients, with levels positively correlated with lactate dehydrogenase and tumor burden. Analysis of ctDNA dynamics revealed ctDNA increase before progression in a subset of patients (5 of 12 patients, 42%). After treatment initiation, six of seven (86%) patients showed ctDNA clearance or decrease. Patients with undetectable ctDNA 2-4 months after the start of treatment had significantly improved progression-free survival (<em>P</em> = 0.024), and a non-significant improvement in overall survival.</div></div><div><h3>Conclusions</h3><div>In patients with UM liver metastases treated with combined hepatic perfusion and immune checkpoint inhibition, ctDNA may serve as a predictive biomarker and warrants further validation.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101079"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书